接受SGLT2抑制剂治疗的系统性红斑狼疮患者的肾脏结局:一项全国性队列研究
该回顾性真实世界分析基于Clalit健康服务SLE登记库(4354例SLE患者),采用两步倾向评分匹配比较2015至2022年间启动SGLT2抑制剂者与未使用者的肾脏结局。匹配后SGLT2抑制剂使用者260例、非使用者413例,24个月时使用者eGFR为71.2 mL/min/1.73 m²(95%CI 69.1-74.9),非使用者为65.4 mL/min/1.73 m²(95%CI 62.5-68.4),p<0.001。SGLT2抑制剂使用与eGFR快速下降风险降低(HR 0.74,95%CI 0.59-0.92,p=0.01)及复合结局风险降低(HR 0.72,95%CI 0.53-0.97,p=0.03)相关。
要点
- 匹配后24个月,SGLT2抑制剂使用者eGFR为71.2 mL/min/1.73 m²,非使用者为65.4 mL/min/1.73 m²(p<0.001)。
- SGLT2抑制剂使用与eGFR快速下降风险降低相关(HR 0.74,95%CI 0.59-0.92,p=0.01)。
- SGLT2抑制剂使用与复合肾脏结局风险降低相关(HR 0.72,95%CI 0.53-0.97,p=0.03)。
核心结论
- 在SLE患者中,暴露于SGLT2抑制剂与肾功能改善及不良肾脏结局风险降低相关。
研究设计与样本
- 回顾性真实世界分析,使用Clalit健康服务SLE登记库(CHS-SLE登记库),该全国性队列包含4354例SLE患者。
- 对2015至2022年间启动SGLT2抑制剂的SLE患者进行两步倾向评分匹配分析。
- 主要结局为24个月时的eGFR;同时评估SGLT2抑制剂使用者与非使用者24个月时eGFR快速下降、eGFR下降≥30%、新发终末期肾病(ESKD)及其复合结局的无事件概率。
- 按基线患者特征分层进行eGFR变化的亚组分析。
主要发现
- 基线时,260例SGLT2抑制剂使用者与413例非使用者完成匹配。
- 匹配后两组基线eGFR相似(71.0 vs. 70.0 mL/min/1.73 m²,p=0.7)。
- 24个月时,SGLT2抑制剂使用者eGFR为71.2 mL/min/1.73 m²(95%CI 69.1-74.9),非使用者为65.4 mL/min/1.73 m²(95%CI 62.5-68.4),p<0.001。
- SGLT2抑制剂使用与eGFR快速下降风险降低相关(HR 0.74,95%CI 0.59-0.92,p=0.01)。
- SGLT2抑制剂使用与复合结局风险降低相关(HR 0.72,95%CI 0.53-0.97,p=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of SGLT2 inhibitors on the estimated glomerular filtration rate (eGFR) over time in patients with systemic lupus erythematosus (SLE). METHODS: This was a retrospective real-world analysis using the Clalit Health Services SLE registry (CHS-SLE registry), a national cohort of 4354 SLE patients. We conducted a two-step propensity-score matching analysis of SLE patients who initiated SGLT2 inhibitors between 2015 and 2022. The primary outcome was the eGFR at 24 months. We also assessed the event-free probability for SGLT2 inhibitor users versus non-users regarding a rapid decline in eGFR, ≥30 % eGFR decline, new-onset end-stage kidney disease (ESKD), and a composite of these outcomes at 24 months. Additionally, we performed subgroup analyses of eGFR changes stratified by baseline patient characteristics. RESULTS: At baseline, 260 SGLT2 inhibitor users were matched with 413 non-users. The baseline eGFR after matching was similar between the two groups (71.0 vs. 70.0 mL/min/1.73 m², p = 0.7). At 24 months, the eGFR was 71.2 mL/min/1.73 m² (95 % CI 69.1-74.9) in the SGLT2 inhibitor users and 65.4 mL/min/1.73 m² (95 % CI 62.5-68.4) in the non-user group (p < 0.001). The use of SGLT2 inhibitors was associated with a reduced risk of developing a rapid decline in eGFR (HR 0.74, 95 % CI 0.59-0.92, p = 0.01), and a reduced risk of developing the composite outcome (HR 0.72, 95 % CI 0.53-0.97, p = 0.03). CONCLUSIONS: In SLE patients, exposure to SGLT2 inhibitors was associated with improved kidney function and a reduced risk of developing adverse kidney outcomes.
引用
- Sagy I, Shitrit I, Abuhasira R, et al. Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study. Semin Arthritis Rheum. 2025. PMID: 40398102. doi:10.1016/j.semarthrit.2025.152746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。